Your institution may have access to this item. Find your institution then sign in to continue.
Title
Bevacizumab/Paclitaxel Granted Accelerated Approval for First-Line Breast Cancer Treatment.
Abstract
The article reports that the U.S. Food and Drug Administration has granted accelerated approval for bevacizumab/paclitaxel combination for first-line treatment of breast cancer. The approval is based on a phase III trial which showed that bevacizumab, in combination with paclitaxel, resulted in a 52% reduction in the risk of breast cancer progression or death.